Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19

The type 2 coronavirus causes severe acute respiratory syndrome (SARS-CoV-2) and produces pneumonia with pulmonary alveolar collapse. In some cases it also sepsis septic shock. There is no specific treatment for disease 2019 (COVID-19). Vitamin C (Vit C), E E), N-acetylcysteine (NAC) Melatonin (MT) increase the intracellular content of GSH, kidnap free radicals protect DNA, proteins in cytosol lipids cell membranes. Pentoxifylline (Px) has anti-inflammatory activities. Here we evaluate effect Vit C, E, NAC, MT plus Px COVID-19 patients moderate pneumonia. 110 either sex were included. They divided into five groups 22 each. Group 1 received + Px, group 3 NAC 4 5 only Px. Oxidative stress (OS) markers such as lipid peroxidation (LPO) levels, total antioxidant capacity (TAC) nitrites (NO2–) evaluated plasma. therapy improved survival scores including Sequential Organ Failure Assessment (SOFA), Acute Physiology chronic Health Evaluation II (Apache II), Simplified Score (SAPS Critical Illness Risk Score, Launched during crisis (COVIDGRAM) Glasgow Coma Scale (GCS). We found that LPO (p?0.04) inflammation interleukin-6 (IL-6, p? 0.01), reactive protein (CRP, p ? 0.01) procalcitonin (PCT, 0.05) elevated. TAC (p 0.03) NO2– 0.04) themselves diminished upon admission to hospital. different antioxidants reversed this alteration at end treatment. supplements could decelerate aggressive lethal development COVID-19. Antioxidant can be effective pandemia since improves SOFA, Apache II, SAPS COVIDGRAM, GCS by lowering LPO, IL-6, CRP, PCT increasing systemic NO2–.